OriGene社 A potential target for prostate cancer cure
FOLH1 (folate hydrolase 1), also known as prostate-specific membrane antigen (PSMA), is an established prostate cancer cell marker that is widely used in diagnosis and therapies. PSMA is a type II transmembrane glycoprotein with most of its mass exposed on the cell surface. In contrast to its modest expression in healthy prostates, brains, and salivary glands, PSMA is abundantly present in the intestines. The extracellular domain of PSMA acts as a glutamate carboxypeptidase on different substrates, including the nutrient folate (in intestines) and the neuropeptide N-acetyl-l-aspartyl-l-glutamate (in brains). Mutations or aberrantly expression of FOLH1 can result in impaired intestinal absorption of dietary folates or glutamate excitotoxicity in the brain, respectively.
Although PSMA is expressed in many cancer types (e.g. bladder, brain, kidney, lung, thyroid gland), its overexpression correlated with progression and metastasis of prostate cancer suggesting that PSMA may play a functional role in prostate cancer progression. Read the report
Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。